Torrent Pharmaceuticals Limited Stock NSE India S.E.

Equities

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:49 2024-04-19 am EDT 5-day change 1st Jan Change
2,539 INR -0.29% Intraday chart for Torrent Pharmaceuticals Limited -1.49% +10.14%
Sales 2024 * 108B 1.3B Sales 2025 * 122B 1.46B Capitalization 859B 10.3B
Net income 2024 * 16.43B 197M Net income 2025 * 20.55B 247M EV / Sales 2024 * 8.28 x
Net Debt 2024 * 37.16B 446M Net Debt 2025 * 25.27B 303M EV / Sales 2025 * 7.25 x
P/E ratio 2024 *
52.9 x
P/E ratio 2025 *
41.8 x
Employees 13,247
Yield 2024 *
0.85%
Yield 2025 *
0.95%
Free-Float 28.64%
More Fundamentals * Assessed data
Dynamic Chart
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60 CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024 CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy MT
Torrent Pharmaceuticals Posts Gains in Fiscal Q3 Consolidated Net Profit MT
Torrent Pharmaceuticals' Consolidated Profit in Fiscal Q3 MT
Transcript : Torrent Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 02, 2024
India's Torrent Pharma posts higher Q3 profit on strong domestic demand RE
Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024 CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO RE
Torrent Pharmaceuticals Forms New Wholly-Owned Arm in Colombia MT
Torrent Pharmaceuticals' Oral Oncology Plant Gets Fives Observations from US FDA MT
More news

Latest transcript on Torrent Pharmaceuticals Limited

1 day-0.29%
1 week-1.49%
Current month-2.35%
1 month+1.52%
3 months+3.07%
6 months+32.32%
Current year+10.14%
More quotes
1 week
2 505.30
Extreme 2505.3
2 585.50
1 month
2 500.50
Extreme 2500.5
2 689.70
Current year
2 291.60
Extreme 2291.6
2 744.00
1 year
1 591.25
Extreme 1591.25
2 744.00
3 years
1 237.75
Extreme 1237.75
2 744.00
5 years
726.00
Extreme 726
2 744.00
10 years
271.20
Extreme 271.2
2 744.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO - -
Compliance Officer - 22-07-31
Chief Operating Officer 47 19-07-31
Members of the board TitleAgeSince
Director/Board Member 70 82-06-22
Chairman 60 85-12-31
Director/Board Member 57 19-03-06
More insiders
Date Price Change Volume
24-04-19 2,539 -0.29% 287,483
24-04-18 2,547 +0.36% 264,434
24-04-16 2,538 +0.70% 119,210
24-04-15 2,520 -2.24% 201,879
24-04-12 2,578 -0.05% 132,838

Delayed Quote NSE India S.E., April 19, 2024 at 07:43 am EDT

More quotes
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
2,537 INR
Average target price
2,728 INR
Spread / Average Target
+7.55%
Consensus